Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of ABX464 in Healthy Males
NCT02731885Phase 1Completed
- Sponsor
- Abivax
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of obefazimod in ulcerative colitis (UC) and human immunodeficiency virus infection (HIV) (4 arms), sponsored by Abivax. Primary endpoints: Area under the plasma concentration versus time curve at 45 days and Peak Plasma Concentration at 45 days. Started Sep 2014; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02731885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731885.